An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function
Clinical Pharmacology & Therapeutics · 2026-04 · 119 (4) · 838-845
DOI: 10.1002/cpt.70190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 03.01.2026. Verfasst von Yan Jin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Exploratory Medicine and Pharmacology, Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Pharmacokinetics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate (eGFR) over the Cockcroft‐Gault (CG) equation to determine renal function; (2) the designs for dedicated renal impairment studies; and (3) characterizing the impact of impaired renal impairment in phase 2/3 trials. The use of absolute eGFR for dosing recommendations, differentiation between intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT) in study design, and a preference for regression analysis over categorical analysis to model the relationship between renal function and PK parameters were also discussed. The updates in the FDA guidance resulted in better alignment with the European Medicines Agency (EMA) guidance on this topic, making global drug development more efficient. The manuscript also presented challenges in using different eGFR equations, the impact of protein binding on dose determination, and the need for further guidance on pediatric equations and novel drug modalities. In conclusion, the manuscript underscores the significance of the updated FDA guidance in enhancing the design, implementation, and data analysis of renal impairment studies while identifying areas for future updates to address emerging topics in drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Exploratory Medicine and Pharmacology, Eli Lilly and Company, Indianapolis, Indiana, USA.
- Boehringer Ingelheim Pharma Inc, Ridgefield, Connecticut, USA.
- Takeda Pharmaceutical Inc., Cambridge, Massachusetts, USA.
- Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
- BeOne Medicines USA, Inc., San Carlos, California, USA.
- Johnson & Johnson Innovative Medicine R&D, Raritan, New Jersey, USA.
ORCID-Profile: Yan Jin, Mariam A Ahmed, Vaishali Sahasrabudhe, Islam R Younis
Zitieren
APA
Jin, Y., Sharma, A., Ahmed, M. A., Cheeti, S., Ou, Y., Devineni, D., Chen, Y., Kanodia, J. S., Abouelhassan, Y., Noormohamed, N., Zhou, J., Marroum, P., Sahasrabudhe, V., & Younis, I. R. (2026). An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function. Clinical Pharmacology & Therapeutics, 119(4), 838-845. https://doi.org/10.1002/cpt.70190
Vancouver
Jin Y, Sharma A, Ahmed MA, Cheeti S, Ou Y, Devineni D, et al. An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function. Clinical Pharmacology & Therapeutics. 2026;119(4):838-845. doi:10.1002/cpt.70190
BibTeX
@article{Jin2026,
author = {Jin, Yan and Sharma, Ashish and Ahmed, Mariam A and Cheeti, Sravanthi and Ou, Ying and Devineni, Damayanthi and Chen, Yizhe and Kanodia, Jitendra S and Abouelhassan, Yasmeen and Noormohamed, Nadia and Zhou, Jin and Marroum, Patrick and Sahasrabudhe, Vaishali and Younis, Islam R},
title = {An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {4},
pages = {838--845},
doi = {10.1002/cpt.70190}
}
EUVIMED